Using natural compounds to target KRAS mutated non-small cell lung cancer

Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity,and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant-based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and downstream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.

Automated summary

Approximately 85% of lung cancer cases are classified as non-small cell lung cancer (NSCLC), with KRAS mutations frequently occurring and leading to decreased overall survival. Plant-based compounds show promise in targeting KRAS-mutated NSCLC cells, inhibiting signaling pathways and offering a wider therapeutic index compared to traditional chemotherapeutic drugs. Further research is needed to explore the potential benefits of natural compounds in treating KRAS-mutant NSCLC.